Company intelligence / Profile preview

LoopLab Bio

Vienna, Vienna, Austrialooplab.bio ↗

Ownership: Private
Employees: ~24
Development stage: Preclinical

Overview

LoopLab Bio develops a new class of virus-based therapeutics called Self-Amplifying Biologics (“SelfAmps”), designed for targeted treatment of immunological and potentially other serious diseases. The technology involves engineering viral backbones for cell/tissue specificity, delivering disease-relevant payloads with immune modulation. As of early 2024/2025, the company appears to be in preclinical development with no disclosed clinical results or programs yet in human trials.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Modalities: Self-Amplifying Biologics (SelfAmps)novel virus-based therapeutics
Industry: Biotech

Beyond the preview

Go deeper on LoopLab Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LoopLab Bio.

Explore the full profile